The present disclosure relates to 2′3′ cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.

The present invention relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer and autoimmunity.

The present invention relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer and autoimmunity.

The disclosure provides, among other things, methods and uses for treating a disease or disorder, particularly a cancer, in a patient, comprising conjointly administering a CTLA4 inhibitor (e.g., an anti-CTLA4 antibody) and a STING agonist to the patient, wherein the CTLA4 inhibitor is administered intratumorally to the patient. The STING agonist can be administered intratumorally, orally or systemically (e.g., intravenously, intramuscularly, or subcutaneously) to the patient.

The disclosure provides, among other things, methods and uses for treating a disease or disorder, particularly a cancer, in a patient, comprising conjointly administering a CTLA4 inhibitor (e.g., an anti-CTLA4 antibody) and a STING agonist to the patient, wherein the CTLA4 inhibitor is administered intratumorally to the patient. The STING agonist can be administered intratumorally, orally or systemically (e.g., intravenously, intramuscularly, or subcutaneously) to the patient.

The present invention provides stable topical ophthalmic preparations of muscarinic agonist for the treatment of dry eye disease. The composition can include a polyunsaturated fatty acid.

The present invention provides stable topical ophthalmic preparations of muscarinic agonist for the treatment of dry eye disease. The composition can include a polyunsaturated fatty acid.

The present invention provides stable topical ophthalmic preparations of muscarinic agonist for the treatment of dry eye disease. The composition can include a polyunsaturated fatty acid.

A drug delivery system that includes nicotinamide adenine dinucleotide or a derivative or a precursor thereof, and a chemical drug delivery enhancer composition. The drug delivery system enhances the delivery of the nicotinamide adenine dinucleotide or derivatives or precursors thereof through different delivery routes.

A drug delivery system that includes nicotinamide adenine dinucleotide or a derivative or a precursor thereof, and a chemical drug delivery enhancer composition. The drug delivery system enhances the delivery of the nicotinamide adenine dinucleotide or derivatives or precursors thereof through different delivery routes.